ACH
JUNO

ArrowMark Colorado Holdings’s Juno Therapeutics, Inc. JUNO Stock Holding History

ArrowMark Colorado Holdings’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-1,212,051
Closed -$55.4M – 356
2017
Q4 		$55.4M Sell
1,212,051
-101,881
-8% -$5.08M 0.56% 65
2017
Q3 		$58.9M Sell
1,313,932
-308,448
-19% -$10.5M 0.67% 51
2017
Q2 		$48.5M Buy
1,622,380
+94,674
+6% +$2.34M 0.6% 59
2017
Q1 		$33.9M Buy
1,527,706
+738,986
+94% +$15.9M 0.46% 77
2016
Q4 		$14.9M Sell
788,720
-86,751
-10% -$2.12M 0.23% 110
2016
Q3 		$26.3M Buy
875,471
+348,754
+66% +$10.8M 0.48% 75
2016
Q2 		$20.2M Buy
526,717
+36,273
+7% +$1.51M 0.41% 86
2016
Q1 		$18.7M Buy
490,444
+106,695
+28% +$3.72M 0.42% 84
2015
Q4 		$16.9M Buy
383,749
+410
+0.1% +$20.3K 0.46% 72
2015
Q3 		$15.6M Buy
383,339
+48,078
+14% +$2.11M 0.43% 69
2015
Q2 		$17.9M Buy
335,261
+40,734
+14% +$2.16M 0.44% 66
2015
Q1 		$17.9M Buy
294,527
+67,033
+29% +$3.25M 0.46% 68
2014
Q4 		$11.9M Buy
+227,494
New +$10.2M 0.31% 96

Other funds holding JUNO

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

ArrowMark Colorado Holdings's JUNO Position: Q1 2018 in Review

ArrowMark Colorado Holdings sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 1,212,051 shares — an estimated $55.4M sold.

ArrowMark Colorado Holdings first reported a position in JUNO in Q4 2014 and held it in 13 quarters. The position peaked at $58.9M in Q3 2017. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

  • ArrowMark Colorado Holdings reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • ArrowMark Colorado Holdings sold 1,212,051 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $55.4M.
  • ArrowMark Colorado Holdings first reported a position in Juno Therapeutics, Inc. in Q4 2014 and held it in 13 quarters.
  • ArrowMark Colorado Holdings's Juno Therapeutics, Inc. position peaked at $58.9M in Q3 2017.
  • 2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on ArrowMark Colorado Holdings's 13F filing for Q1 2018, filed 15 May 2018.